Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q4 FY25-26 | Q4 FY24-25 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,516.60 | 4,417.00 | 2.25 | 16,927.00 | 15,261.70 | 10.91 |
| Expenses | 3,576.70 | 3,338.80 | 7.13 | 13,874.60 | 12,095.40 | 14.71 |
| Other Income | 52.50 | 57.30 | -8.38 | 342.50 | 1,304.70 | -73.75 |
| Operating Profit | 939.90 | 1,078.20 | -12.83 | 3,394.90 | 4,471.00 | -24.07 |
| Depreciation | 513.40 | 436.30 | 17.67 | 1,956.70 | 1,687.00 | 15.99 |
| Interest | 231.50 | 212.40 | 8.99 | 990.30 | 897.40 | 10.35 |
| Profit Before Tax | 247.50 | 486.80 | -49.16 | 447.90 | 1,886.60 | -76.26 |
| Tax | 48.90 | 27.40 | 78.47 | 443.60 | 389.20 | 13.98 |
| Net Profit | 198.60 | 459.40 | -56.77 | 368.80 | 1,429.40 | -74.20 |
| Category | Q4 FY25-26 | Q4 FY24-25 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 604.70 | 643.80 | -6.07 | 2,346.40 | 2,242.60 | 4.63 |
| Expenses | 544.20 | 581.80 | -6.46 | 2,335.40 | 2,066.80 | 13.00 |
| Other Income | 49.80 | 62.70 | -20.57 | 319.70 | 849.80 | -62.38 |
| Operating Profit | 479.50 | 565.40 | -15.19 | 330.70 | 1,025.60 | -67.76 |
| Depreciation | 36.20 | 33.00 | 9.70 | 137.30 | 127.80 | 7.43 |
| Interest | 16.70 | 56.70 | -70.55 | 142.40 | 236.90 | -39.89 |
| Profit Before Tax | 57.40 | 35.00 | 64.00 | 51.00 | 660.90 | -92.28 |
| Tax | 6.40 | 13.80 | -53.62 | 12.00 | 50.50 | -76.24 |
| Net Profit | 51.00 | 21.20 | 140.57 | 37.20 | 609.30 | -93.89 |
| Category | Q4 FY25-26 | Q3 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,516.60 | 4,173.00 | 8.23 |
| Expenses | 3,576.70 | 3,632.90 | -1.55 |
| Other Income | 52.50 | 117.30 | -55.24 |
| Operating Profit | 939.90 | 540.10 | 74.02 |
| Depreciation | 513.40 | 515.30 | -0.37 |
| Interest | 231.50 | 209.90 | 10.29 |
| Profit Before Tax | 247.50 | -67.80 | -465.04 |
| Tax | 48.90 | -16.00 | -405.63 |
| Net Profit | 198.60 | -51.80 | -483.40 |
| Category | Q4 FY25-26 | Q3 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 604.70 | 621.30 | -2.67 |
| Expenses | 544.20 | 744.30 | -26.88 |
| Other Income | 49.80 | 74.80 | -33.42 |
| Operating Profit | 479.50 | 345.60 | 38.74 |
| Depreciation | 36.20 | 34.00 | 6.47 |
| Interest | 16.70 | 2.30 | 626.09 |
| Profit Before Tax | 57.40 | -84.50 | -167.93 |
| Tax | 6.40 | -8.10 | -179.01 |
| Net Profit | 51.00 | -76.40 | -166.75 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .
